In this podcast episode, your host, Chris Leidli, MS, MBA, goes beyond the ASCO 2024 headlines and puts a spotlight on the new clinical data for advanced therapies you don't want to miss.
In this episode, we preview the top American Society of Gene and Cell Therapy (ASGCT) 2024 annual meeting abstracts with guests Dr. Emily Walsh Martin from Tremont Therapeutics Consulting and Lynnea Olivarez, Incoming Chair of the ASGCT Communications Committee.
Over the years, electronic health records (EHRs) have revolutionized medical practice, digitizing patient data and streamlining care. But the current systems are not well suited to support collection of real-world data or the tracking of longitudinal outcomes across patient populations. This is particularly true for hematopoietic stem cell transplant and cellular therapies. Our special guest, Dr. Wayne Liang is a leader in the stem cell transplant and cell therapy informatics field. Wayne is Director of Informatics Education and Outreach at Children's Healthcare of Atlanta, he is also a pediatric hematologist/oncologist at Aflac Cancer & Blood Disorders Center, and Assistant Professor of Pediatrics at Emory University.
Our guest for this podcast episode is Simon Arkell, CEO of Ryght. Ryght is developing the next generation of safe and secure generative AI to empower Life Science companies to ingest real-time data and make actionable knowledge directly available to discovery, clinical, and commercial teams.
Our guest for this podcast episode is Doron Behar, MD, PhD, co-founder and CEO of Igentify, a digital health, artificial intelligence and genetic counseling company. In this episode, Dr. Behar shares how his company has developed a medical-grade tech platform that optimizes genomic workflows and produces AI-generated personalized genetic counseling for patients.
This episode features a preview of the American Society of Gene and Cell Therapy Annual Meeting scientific symposium on the impact of Generative AI on cell and gene therapy (CGT); best practices and real-world applications for communicators. Dr. Rory Bricker-Anthony shares insight into what attendees can expect to learn from the May 2024 session, including current tools and applications for CGT communicators.
Our guest in this podcast episode is Chris Dokomajilar, Founder and CEO of DealForma. DealForma’s comprehensive life science database includes meticulously researched licensing deal financial comps, up-to-date profiles, and historic company and pipeline data. In this special spotlight episode, we take a deeper dive into the investment landscape for advanced therapies and also AI investment and partnership activity in the biopharma space.
We often don’t get the chance to hear from survivors and patient advocates whose lives have been impacted by advanced medicines; so that makes this podcast episode special as we talk to Chris White, a cancer survivor who faced the unimaginable when diagnosed with Mucosal Melanoma in 2018—a rare and aggressive cancer which makes Chris's journey even more exceptional. Today, Chris is not just a survivor; he's a beacon of inspiration. He has redirected his energy towards advocacy, prevention, and raising awareness of the complexities associated with Mucosal Melanoma. Tune in to listen to Chris's extraordinary odyssey, exploring the challenges he faced throughout his treatment journey and proving that with resilience, determination, and hope, anything is possible.
Our guest for this podcast episode is Mark Carbone, the CEO of PN Medical. PN Medical is a leader in respiratory care and research. The company created “The Breather”, the world’s first combined respiratory muscle training device to strengthen respiratory muscles to optimize blood flow, lung function and strengthen the cardiopulmonary system.
In part 2 of this special round table podcast series, we discuss the future trends and advances in cell therapy manufacturing and the impact of AI on the evolving cell therapy analytics space.
In part 1 of this special round table podcast series, we discuss the current trends and advances in cell therapy manufacturing and the impact of evolving manufacturing processes on the analytics space.
Our guest for this podcast episode is Laura Hobbs, Director of Healthcare Policy at the American Action Forum. In this episode, we discuss the Inflation Reduction Act impact on Pharma and Patient Access, along with 340b drug pricing and new PBM utilization controls. Learn more about the American Action Forum, and subscribe to their weekly newsletter here: https://www.americanactionforum.org/
In this special episode, listen to Emily Walsh Martin, PhD, Principal at Tremont Therapeutics Consulting, as she shares some of the key highlights from the American Society of Gene and Cell Therapy’s Policy Summit that was held in Washington, DC, on September 18th and 19th, 2023. Check out the full program and register to view the on-demand content online at asgct.org/advocacy/policy-summit/agenda
The Inflation Reduction Act was signed into law in August 2022. In this podcast episode, we look into what lies ahead as the policy implementation begins. Our guest in this episode is Dr. Robert Popovian, a clinical pharmacist and health economist with deep expertise in health policy, drug pricing and affordability, access, and patient advocacy.
Our guests for this podcast episode are the co-founders of Ratio Therapeutics, CEO Jack Hoppin, PhD, and Chief Scientific Officer, John Babich, PhD. Ratio Therapeutics's mission is to develop best-in-class radiopharmaceuticals for the treatment of cancers.
Listen to Francesca Cook, VP of Market Access at Regenexbio, as she provides an overview of the program and what to expect at the American Society of Gene and Cell Therapy’s upcoming Policy Summit being held in Washington, DC, on September 18th and 19th, 2023. Check out the full program and register online at https://asgct.org/advocacy/policy-summit/agenda
In this podcast episode, our guest is Mark McDonough, CEO of ChromaCode. ChromaCode is an innovator in genomics with a multiplexing platform that is driving integration from laboratories to physicians to patients, connecting them to the right treatment through its proven HDPCR™ multiplexing platform. This adaptable technology expands the accessibility of diagnostic applications to patient communities with a cost effective and scalable dPCR-based solution compatible with existing instrumentation and using standard workflows
In this podcast episode, our guest is Dr. Fahar Merchant, President and CEO of Medicenna Therapeutics. Medicenna is a clinical stage immunotherapy company that engineers novel, powerful and proprietary interleukins leveraging their Superkine Platform to modulate, fine-tune or amplify the immune system to tackle the most challenging diseases, including a broad range of cancers.
In this podcast episode, Tomasz George, Chief Scientific Officer at Virax Biolabs, shares how the company's ViraxImmune™ technology platform will empower patients to take control of their health and make informed decisions on how to respond to current and future viral threats. The company hopes their ViraxImmune™ platform will shift the way individuals are able to manage aspects of their immune health.
In this podcast episode, Dr. Michael Alonso, VP of Immunology and Pharmacology at Bolt Biotherapeutics, discusses how the company is developing cancer therapies that engage the innate immune system to generate robust anti-tumor responses.